Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Jovana Markovic, Ruomeng Li, Rajendra Khanal, Qi Peng, Selina Möbus, Qinggong Yuan, Bastian Engel, Richard Taubert, Florian W R Vondran, Heike Bantel, Manvendra K Singh, Tobias Cantz, Hildegard Büning, Heiner Wedemeyer, Michael Ott, Asha Balakrishnan, Amar Deep Sharma
BACKGROUND & AIMS: Liver fibrosis and its end-stage form known as cirrhosis contributes to millions of deaths annually. The lack of robust anti-fibrotic molecules is in part attributed to absence of any functional screens to identify molecular regulators using patient-derived primary human hepatic myofibroblasts, which are key drivers of fibrosis. METHODS: Here, to identify robust regulators of fibrosis, we performed functional microRNA screenings in primary human hepatic myofibroblasts followed by in vivo validation in three independent mouse models of fibrosis (toxin, cholestasis and MASH)...
August 30, 2024: Journal of Hepatology
#2
LETTER
Junkun Zhu
No abstract text is available yet for this article.
August 30, 2024: Journal of Hepatology
#3
JOURNAL ARTICLE
Qi Zhong, Rui Zhou, Yi-Ning Huang, Rui-Dian Huang, Fu-Rong Li, Hao-Wen Chen, Yan-Fei Wei, Kuan Liu, Bi-Fei Cao, Kai-Yue Liao, Zheng-Yun Xu, Shi-Ao Wang, Xian-Bo Wu
BACKGROUND & AIMS: Frailty is associated with multiple morbidities. However, its effect on chronic liver diseases remains largely unexplored. This study evaluated the association of frailty with the risk of incident metabolic dysfunction-associated steatotic liver disease (MASLD), cirrhosis, liver cancer, and liver-related mortality. METHODS: A total of 339,298 participants without prior liver diseases from the UK Biobank were included. Baseline frailty was assessed by using physical frailty and the frailty index, categorizing participants as nonfrail, prefrail, or frail...
August 30, 2024: Journal of Hepatology
#4
LETTER
Wilhelmus J Kwanten, Benedikt Silvester Hofer, Sven Francque
No abstract text is available yet for this article.
August 30, 2024: Journal of Hepatology
#5
LETTER
Win Min Han, Tanakorn Apornpong, Natthaya Chuaypen, Pisit Tangkijvanich, Anchalee Avihingsanon
No abstract text is available yet for this article.
August 30, 2024: Journal of Hepatology
#6
LETTER
Sahith Kudaravalli, Linda Henry, Mindie H Nguyen
No abstract text is available yet for this article.
August 30, 2024: Journal of Hepatology
#7
LETTER
Gautam Mehta, Rajiv Jalan
No abstract text is available yet for this article.
August 30, 2024: Journal of Hepatology
#8
JOURNAL ARTICLE
Moon Haeng Hur, Terry Cheuk-Fung Yip, Seung Up Kim, Hyun Woong Lee, Han Ah Lee, Hyung-Chul Lee, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Jun Yong Park, Sang Hoon Ahn, Beom Kyung Kim, Hwi Young Kim, Yeon Seok Seo, Hyunjae Shin, Jeayeon Park, Yunmi Ko, Youngsu Park, Yun Bin Lee, Su Jong Yu, Sang Hyub Lee, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee
BACKGROUND & AIMS: The risk of hepatocellular carcinoma (HCC) and hepatic decompensation persists after hepatitis B surface antigen (HBsAg) seroclearance. This study aimed to develop and validate a machine learning model to predict the risk of liver-related outcomes (LROs) following HBsAg seroclearance. METHODS: A total of 4,787 consecutive patients who achieved HBsAg seroclearance between 2000 and 2022 were enrolled from 6 centers in South Korea and a territory-wide database in Hong Kong, comprising the training (n=944), internal validation (n=1,102), and external validation (n=2,741) cohorts...
August 30, 2024: Journal of Hepatology
#9
JOURNAL ARTICLE
Sabine Kahl, Klaus Straßburger, Giovanni Pacini, Nina Trinks, Kalliopi Pafili, Lucia Mastrototaro, Bedair Dewidar, Theresia Sarabhai, Sandra Trenkamp, Irene Esposito, Matthias Schlensak, Frank A Granderath, Michael Roden
BACKGROUND & AIMS: Hepatic mitochondrial respiration is higher in steatosis, but lower in overt type 2 diabetes. We hypothesized that hepatic OXPHOS capacity increases with a greater degree of insulin resistance in obesity, independent of other metabolic diseases. METHODS: We analysed 65 humans without diabetes (BMI 50±7 kg/m2 , HbA1c 5.5±0.4%) undergoing bariatric surgery. MASLD stages were assessed by histology, whole-body insulin sensitivity (PREDIcted-M index) by oral glucose tolerance tests, and maximal ADP-stimulated mitochondrial OXPHOS capacity by high-resolution respirometry of liver samples...
August 30, 2024: Journal of Hepatology
#10
LETTER
Sonia Torres, Cautar El Maimouni, Gilberto Herrera, Javier Fernandez
No abstract text is available yet for this article.
August 30, 2024: Journal of Hepatology
#11
JOURNAL ARTICLE
Maria Buti, Jeong Heo, Yasuhito Tanaka, Pietro Andreone, Masanori Atsukawa, Joaquín Cabezas, Eric Chak, Carla S Coffin, Kei Fujiwara, Natalya Gankina, Stuart C Gordon, Ewa Janczewska, Atsumasa Komori, Pietro Lampertico, Stuart McPherson, Vyacheslav Morozov, Robert Plesniak, Sébastien Poulin, Pablo Ryan, Olga Sagalova, Guoping Sheng, Natalya Voloshina, Qing Xie, Hyung Joon Yim, Susan Dixon, Melanie Paff, Leigh Felton, Maximilian Lee, Thomas Greene, Jessica Lim, Divya Lakshminarayanan, Grant McGonagle, Helene Plein, Amir Youssef, Rob Elston, Stuart Kendrick, Dickens Theodore
BACKGROUND & AIMS: Bepirovirsen, an antisense oligonucleotide, induces sustained hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA below lower limit of quantification (<LLOQ) in a subset of patients. The B-Together study investigated if sequential bepirovirsen and pegylated interferon-α-2a (Peg-IFN) therapy can reduce relapse and improve response rates. METHODS: Phase 2b, multicentre, randomised, open-label trial. Participants on stable nucleos(t)ide analog (NA) therapy were randomised 1:1 to bepirovirsen 300 mg once weekly (plus loading dose on Days 4 and 11) for 24 (Arm 1) or 12 (Arm 2) weeks followed by Peg-IFN 180 mcg once weekly for up to 24 weeks, with up to 36 weeks follow-up...
August 28, 2024: Journal of Hepatology
#12
JOURNAL ARTICLE
Zobair M Younossi, Shira Zelber-Sagi, Carina Kuglemas, Jeffrey V Lazarus, Annette Paik, Leyla de Avila, Lynn Gerber, James M Paik
BACKGROUND: The burden of MASLD is growing across the globe. This study explores association of food insecurity with MASLD prevalence and liver-related mortality (LRM) across the globe. METHODS: The study combines United Nations' country-level food security data with the MASLD data from Global Burden of Disease-2021. Mixed-effects linear regression (MELR) models, accounting for country-level random effects, were used to assess associations of food security indicators with MASLD prevalence and LRM...
August 27, 2024: Journal of Hepatology
#13
JOURNAL ARTICLE
Yong Lv, Qiuhe Wang, Bohan Luo, Wei Bai, Menghao Li, Kai Li, Zhengyu Wang, Dongdong Xia, Wengang Guo, Xiaomei Li, Jie Yuan, Na Zhang, Xing Wang, Huahong Xie, Yanglin Pan, Yongzhan Nie, Zhanxin Yin, Daiming Fan, Guohong Han
BACKGROUND & AIMS: The optimal timing of measurement and hemodynamic targets of portacaval pressure gradient (PPG) after TIPS remains inconclusive. This study aimed to identify the ideal moment of hemodynamic measurements and the optimal target of PPG in patients undergoing covered TIPS for variceal bleeding. METHODS: Between May 2018 and December 2021, 466 consecutive patients with recurrent variceal bleeding treated with covered TIPS were prospectively included...
August 22, 2024: Journal of Hepatology
#14
JOURNAL ARTICLE
Marta Magaz, Heloïse Giudicelli-Lett, Juan G Abraldes, Oana Nicoară-Farcău, Fanny Turon, Neil Rajoriya, Ashish Goel, Karlien Raymenants, Sophie Hillaire, Luis Téllez, Laure Elkrief, Bogdan Procopet, Lara Orts, Filipe Nery, Akash Shukla, Hélène Larrue, Helena Degroote, Victoria Aguilera, Elba LLop, Laura Turco, Federica Indulti, Stefania Gioia, Giulia Tosetti, Niccolò Bitto, Chiara Becchetti, Edilmar Alvarado, Cristina Roig, Raquel Diaz, Michael Praktiknjo, Anna-Lena Konicek, Pol Olivas, José Ignacio Fortea, Helena Masnou, Ángela Puente, Alba Ardèvol, Carmen A Navascués, Marta Romero-Gutiérrez, Bernhard Scheiner, Georg Semmler, Mattias Mandorfer, Filipe Damião, Anna Baiges, Asunción Ojeda, Macarena Simón-Talero, Carlos González-Alayón, Alba Díaz, Ángeles García-Criado, Andrea De Gottardi, Manuel Hernández-Guerra, Joan Genescà, Nicolas Drilhon, Carlos Noronha Ferreira, Thomas Reiberger, Manuel Rodríguez, Rosa María Morillas, Javier Crespo, Jonel Trebicka, Rafael Bañares, Càndid Villanueva, Annalisa Berzigotti, Massimo Primignani, Vincenzo La Mura, Oliviero Riggio, Filippo Schepis, Xavier Verhelst, José Luis Calleja, Christophe Bureau, Agustín Albillos, Frederik Nevens, Virginia Hernández-Gea, Dhiraj Tripathi, Pierre-Emmanuel Rautou, Juan Carlos García-Pagán
BACKGROUND & AIMS: Current knowledge of the natural history of patients with porto-sinusoidal vascular disorder (PSVD) is derived from small studies. The aim of the present study was to determine natural history and prognostic factors using a large multicenter cohort of PSVD patients. METHODS: Retrospective multicentric study of PSVD patients and signs of portal hypertension (PH) prospectively registered in 27 centers. RESULTS: 587 patients were included, median age of 47 years and 38% were women...
August 22, 2024: Journal of Hepatology
#15
JOURNAL ARTICLE
Craig Rosenstengle, Marina Serper, Sumeet K Asrani, Therese Bittermann, Jinyu Du, Tsung-Wei Ma, David Goldberg, Pere Gines, Patrick S Kamath
BACKGROUND & AIMS: Kidney dysfunction is a major determinant of prognosis in patients with decompensated cirrhosis awaiting transplantation. We hypothesized that for identical MELD scores at listing, outcomes before and after liver transplantation may vary if the predominant driver of the MELD score is serum creatinine versus serum bilirubin or INR. METHODS: We evaluated all adult patients registered for liver transplantation (LT) between 2016 - 2020 and excluded patients receiving MELD exceptions or undergoing dual organ transplantation...
August 22, 2024: Journal of Hepatology
#16
JOURNAL ARTICLE
Yasmine J Liu, Masaki Kimura, Xiaoxu Li, Jonathan Sulc, Qi Wang, Sandra Rodríguez-López, Angelique M L Scantlebery, Keno Strotjohann, Hector Gallart-Ayala, Archana Vijayakumar, Robert P Myers, Julijana Ivanisevic, Riekelt H Houtkooper, G Mani Subramanian, Takanori Takebe, Johan Auwerx
BACKGROUND & AIMS: Recent findings reveal the importance of tryptophan-initiated de novo nicotinamide adenine dinucleotide (NAD+ ) synthesis in the liver, a process previously considered secondary to biosynthesis from nicotinamide. The enzyme α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD), primarily expressed in liver and kidney, acts as a modulator of de novo NAD+ synthesis. Boosting NAD+ levels has previously demonstrated remarkable metabolic benefits in mouse models...
August 22, 2024: Journal of Hepatology
#17
JOURNAL ARTICLE
Yu-Hang Zhang, Ran Xie, Chen-Shu Dai, Hong-Wei Gao, Gan Zhou, Tian-Tian Qi, Wen-Yu Wang, Hua Wang, Yi-Min Cui
BACKGROUND & AIMS: As the first approved medication for metabolic dysfunction-associated steatohepatitis (MASH), thyroid hormone receptor-beta (THR-β) agonist MGL-3196 (Resmetirom) is highly spotlighted as the liver-directed, bioactive oral drug. However, it was also identified with remarkable heterogeneity of individual clinical efficacy and its interference with gut microbiota in host hepatoenteral circulation was still undocumented. METHODS: We compared MASH attenuation by MGL-3196 and its derivative drug HSK31679 between germ-free (GF) and specific-pathogen free (SPF) mice to evaluate the role of gut microbiota...
August 22, 2024: Journal of Hepatology
#18
LETTER
Juan Vaz, Jose Willemse, Peter Jepsen
No abstract text is available yet for this article.
August 20, 2024: Journal of Hepatology
#19
JOURNAL ARTICLE
Emilie Crouchet, Mayssa Dachraoui, Frank Jühling, Natascha Roehlen, Marine A Oudot, Sarah C Durand, Clara Ponsolles, Cloé Gadenne, Laura Meiss-Heydmann, Julien Moehlin, Romain Martin, Nicolas Brignon, Fabio Del Zompo, Yuji Teraoka, Hiroshi Aikata, Hiromi Abe-Chayama, Kazuaki Chayama, Antonio Saviano, Danijela Heide, Mihaela Onea, Lucas Geyer, Thibaut Wolf, Emanuele Felli, Patrick Pessaux, Mathias Heikenwälder, Pierre Chambon, Catherine Schuster, Joachim Lupberger, Atish Mukherji, Thomas F Baumert
BACKGROUND & AIMS: Liver fibrosis is the major driver for hepatocellular carcinoma and liver disease related death. Approved anti-fibrotic therapies are absent and compounds in development have limited efficacy. Increased TGF-β signaling drives collagen deposition by hepatic stellate cells (HSC)/myofibroblasts. Here, we aimed to dissect the role of the circadian clock (CC) in controlling TGF-β signaling and liver fibrosis. METHODS: Using CC-mutant mice, enriched HSCs and myofibroblasts obtained from healthy and fibrotic mice in different CC-phases and loss-of-function studies in human hepatocytes and myofibroblasts, we investigated the relationship between CC and TGF-β signaling...
August 20, 2024: Journal of Hepatology
#20
LETTER
So-Young Kim, Eui-Cheol Shin
No abstract text is available yet for this article.
August 19, 2024: Journal of Hepatology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
